Your browser doesn't support javascript.
loading
The Next-Generation Oral Selective Estrogen Receptor Degrader Camizestrant (AZD9833) Suppresses ER+ Breast Cancer Growth and Overcomes Endocrine and CDK4/6 Inhibitor Resistance.
Lawson, Mandy; Cureton, Natalie; Ros, Susana; Cheraghchi-Bashi, Azadeh; Urosevic, Jelena; D'Arcy, Sophie; Delpuech, Oona; DuPont, Michelle; Fisher, David I; Gangl, Eric T; Lewis, Hilary; Trueman, Dawn; Wali, Neha; Williamson, Stuart C; Moss, Jennifer; Montaudon, Elodie; Derrien, Heloise; Marangoni, Elisabetta; Miragaia, Ricardo J; Gagrica, Sladjana; Morentin-Gutierrez, Pablo; Moss, Thomas A; Maglennon, Gareth; Sutton, Daniel; Polanski, Radoslaw; Rosen, Alan; Cairns, Jonathan; Zhang, Pei; Sánchez-Guixé, Mònica; Serra, Violeta; Critchlow, Susan E; Scott, James S; Lindemann, Justin P O; Barry, Simon T; Klinowska, Teresa; Morrow, Christopher J; Carnevalli, Larissa S.
Afiliação
  • Lawson M; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.
  • Cureton N; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.
  • Ros S; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.
  • Cheraghchi-Bashi A; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.
  • Urosevic J; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.
  • D'Arcy S; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.
  • Delpuech O; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.
  • DuPont M; Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts.
  • Fisher DI; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • Gangl ET; Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts.
  • Lewis H; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.
  • Trueman D; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.
  • Wali N; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.
  • Williamson SC; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.
  • Moss J; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.
  • Montaudon E; Institut Curie, Paris, France.
  • Derrien H; Institut Curie, Paris, France.
  • Marangoni E; Institut Curie, Paris, France.
  • Miragaia RJ; Oncology Data Science, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Gagrica S; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.
  • Morentin-Gutierrez P; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.
  • Moss TA; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.
  • Maglennon G; Clinical Pharmacology and Safety Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • Sutton D; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.
  • Polanski R; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • Rosen A; Research and Early Development, Oncology R&D, AstraZeneca, Waltham, Massachusetts.
  • Cairns J; Discovery Sciences, Biopharmaceuticals R&D, AstraZeneca, Cambridge, United Kingdom.
  • Zhang P; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.
  • Sánchez-Guixé M; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Serra V; Experimental Therapeutics Group, Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain.
  • Critchlow SE; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.
  • Scott JS; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.
  • Lindemann JPO; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.
  • Barry ST; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.
  • Klinowska T; Late Development, Oncology R&D, AstraZeneca, Cambridge, United Kingdom.
  • Morrow CJ; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.
  • Carnevalli LS; The Discovery Centre, Biomedical Campus, AstraZeneca, Cambridge, United Kingdom.
Cancer Res ; 83(23): 3989-4004, 2023 12 01.
Article em En | MEDLINE | ID: mdl-37725704
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Limite: Female / Humans Idioma: En Revista: Cancer Res Ano de publicação: 2023 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Neoplasias da Mama Limite: Female / Humans Idioma: En Revista: Cancer Res Ano de publicação: 2023 Tipo de documento: Article